These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26983912)

  • 21. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.
    Kim ST; Jang HL; Lee SJ; Lee J; Choi YL; Kim KM; Cho J; Park SH; Park YS; Lim HY; Yashiro M; Kang WK; Park JO
    Mol Cancer Ther; 2014 Nov; 13(11):2527-36. PubMed ID: 25249557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: a retrospective analysis from a medical center.
    Kuo YC; Liu HT; Lin YL; Yang YC; Yang TS; Liau CT; Shen WC; Hsu HC; Chou WC; Chen JS
    Biomed J; 2014; 37(3):141-6. PubMed ID: 24923572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Xiang XJ; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
    Chemotherapy; 2012; 58(1):1-7. PubMed ID: 22310723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of Oxaliplatin Combination Therapy for Unresectable or Recurrent Gastric Cancer].
    Oikawa Y; Takahashi M; Takahashi S; Matsumoto S; Kenno S; Noguchi K; Kakisaka T; Tahara M; Yamagami H; Ishizu H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1579-1581. PubMed ID: 28133063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
    J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Dong N; Jiang W; Li H; Liu Z; Xu X; Wang M
    Am J Clin Oncol; 2009 Dec; 32(6):559-63. PubMed ID: 19581793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
    Shoji H; Yamada Y; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Anticancer Res; 2015 Sep; 35(9):5055-61. PubMed ID: 26254407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of epirubicin plus oxaliplatin and fluorouracil as first-line chemotherapy for advanced gastric cancer.
    Zhao JG; Xiong JP; Xiang XJ; Qiu F; Zhang L; Yu F
    Ai Zheng; 2009 Jan; 28(1):42-4. PubMed ID: 19448415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
    Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Louvet C; André T; Tigaud JM; Gamelin E; Douillard JY; Brunet R; François E; Jacob JH; Levoir D; Taamma A; Rougier P; Cvitkovic E; de Gramont A
    J Clin Oncol; 2002 Dec; 20(23):4543-8. PubMed ID: 12454110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
    J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A Case of Advanced Gastric Cancer with Severe Jaundice from Multiple Liver Metastases That Was Significantly Improved after Capecitabine plus Oxaliplatin Treatment].
    Takagi H; Ando T; Hosokawa A; Nishino T; Mihara H; Yoshita H; Nakada N; Nanjo S; Miura Y; Kajiura S; Fujinami H; Sugiyama T
    Gan To Kagaku Ryoho; 2016 Sep; 43(9):1117-9. PubMed ID: 27628556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.
    Kim YS; Sym SJ; Park SH; Park I; Hong J; Ahn HK; Park J; Cho EK; Lee WK; Chung M; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):163-9. PubMed ID: 24202666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.